Actinium Pharmaceuticals (ATNM) Competitors $1.71 -0.12 (-6.56%) Closing price 04:00 PM EasternExtended Trading$1.72 +0.01 (+0.29%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock ATNM vs. IPHA, CRGX, VYGR, YMAB, IVA, CRDF, PRME, INMB, TLSA, and MOLNShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Innate Pharma (IPHA), CARGO Therapeutics (CRGX), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), Inventiva (IVA), Cardiff Oncology (CRDF), Prime Medicine (PRME), INmune Bio (INMB), Tiziana Life Sciences (TLSA), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Innate Pharma CARGO Therapeutics Voyager Therapeutics Y-mAbs Therapeutics Inventiva Cardiff Oncology Prime Medicine INmune Bio Tiziana Life Sciences Molecular Partners Actinium Pharmaceuticals (NYSE:ATNM) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends. Does the media favor ATNM or IPHA? In the previous week, Actinium Pharmaceuticals had 22 more articles in the media than Innate Pharma. MarketBeat recorded 24 mentions for Actinium Pharmaceuticals and 2 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.00 beat Actinium Pharmaceuticals' score of -0.05 indicating that Innate Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in ATNM or IPHA? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, ATNM or IPHA? Actinium Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Do analysts rate ATNM or IPHA? Actinium Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 133.92%. Innate Pharma has a consensus target price of $11.00, indicating a potential upside of 414.02%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Innate Pharma is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the MarketBeat Community favor ATNM or IPHA? Innate Pharma received 37 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 60.00% of users gave Innate Pharma an outperform vote while only 47.83% of users gave Actinium Pharmaceuticals an outperform vote. CompanyUnderperformOutperformActinium PharmaceuticalsOutperform Votes1147.83% Underperform Votes1252.17% Innate PharmaOutperform Votes4860.00% Underperform Votes3240.00% Is ATNM or IPHA more profitable? Innate Pharma's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Innate Pharma N/A N/A N/A Which has higher valuation & earnings, ATNM or IPHA? Innate Pharma has higher revenue and earnings than Actinium Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium Pharmaceuticals$81K658.58-$48.82M-$1.39-1.23Innate Pharma$12.62M14.21-$8.19MN/AN/A SummaryInnate Pharma beats Actinium Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$53.35M$6.48B$5.35B$19.38BDividend YieldN/A2.66%5.22%3.84%P/E Ratio-1.238.9226.8434.23Price / Sales658.58250.95391.3934.85Price / CashN/A65.8538.2517.51Price / Book1.316.466.794.69Net Income-$48.82M$143.98M$3.23B$1.02B7 Day Performance17.12%3.04%4.07%-1.34%1 Month Performance42.50%7.44%12.52%9.79%1 Year PerformanceN/A-2.46%16.83%3.27% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals1.2012 of 5 stars$1.71-6.6%$4.00+133.9%N/A$53.35M$81,000.00-1.2330Trending NewsIPHAInnate Pharma1.9456 of 5 stars$2.28-6.8%$11.00+383.5%-25.6%$190.71M$12.62M0.00220CRGXCARGO Therapeutics2.1898 of 5 stars$4.07+1.2%$15.00+268.6%-79.9%$187.67MN/A-0.96116Gap UpVYGRVoyager Therapeutics4.6577 of 5 stars$3.35+5.7%$13.97+316.9%-59.8%$185.30M$80.00M4.72100Gap UpYMABY-mAbs Therapeutics3.4829 of 5 stars$4.07+4.6%$17.40+327.5%-64.2%$184.28M$87.69M-7.54150Analyst ForecastAnalyst RevisionGap UpIVAInventiva1.4902 of 5 stars$3.51-3.0%$10.40+196.3%-17.1%$184.19M$9.20M0.00100CRDFCardiff Oncology1.5695 of 5 stars$2.75+3.4%$12.00+336.4%-13.3%$182.95M$683,000.00-2.9320News CoverageGap UpPRMEPrime Medicine3.7023 of 5 stars$1.34+3.1%$13.14+880.8%-84.4%$175.76M$3.85M-0.65234Trending NewsAnalyst ForecastAnalyst RevisionGap DownINMBINmune Bio1.9459 of 5 stars$7.64+9.6%$22.80+198.4%-31.6%$175.60M$14,000.00-3.5010Positive NewsGap DownTLSATiziana Life Sciences1.0779 of 5 stars$1.50-4.5%N/A+94.8%$175.27MN/A0.008MOLNMolecular Partners1.9518 of 5 stars$4.28+4.4%$12.00+180.4%+5.6%$172.81M$4.97M-1.99180News CoverageEarnings ReportAnalyst RevisionGap Up Related Companies and Tools Related Companies Innate Pharma Alternatives CARGO Therapeutics Alternatives Voyager Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Inventiva Alternatives Cardiff Oncology Alternatives Prime Medicine Alternatives INmune Bio Alternatives Tiziana Life Sciences Alternatives Molecular Partners Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ATNM) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATNM Stock Free ATNM Stock Alerts